Molecular Profile | MET over exp |
Therapy | Telisotuzumab vedotin |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Create By | spatt |
Update By | djd |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | MET over exp | lung adenocarcinoma | predicted - sensitive | Telisotuzumab vedotin | Preclinical - Pdx | Actionable | In a preclinical study, ABBV-399 demonstrated efficacy in MET-expressing lung adenocarcinoma patient-derived xenograft (PDX) models, with the PDX model with higher MET expression levels showing improved tumor growth delay (PMID: 27573171). | 27573171 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(27573171) | ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence. | Full reference... |